Ligand Pharmaceuticals Balance Sheet

Financials in millions NGN. Fiscal year is January - December.

Millions NGN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Cash & Equivalents	177.02	1,191	5,261	850.64	866.19	1,006	Upgrade
Trading Asset Securities	-	-	946.92	-	-	-	Upgrade
Cash & Short-Term Investments	177.02	1,191	6,208	850.64	866.19	1,006	Upgrade
Cash Growth	-95.96%	-80.81%	629.82%	-1.80%	-13.88%	-38.00%	Upgrade
Accounts Receivable	454.69	429.09	948.3	679.45	373.22	100.14	Upgrade
Receivables	543.99	517.9	1,041	747.99	402.06	100.14	Upgrade
Prepaid Expenses	372.84	225.59	149.86	199.04	172.29	152.9	Upgrade
Other Current Assets	834.49	920.36	680.71	567.52	51.28	45.63	Upgrade
Total Current Assets	1,928	2,855	8,079	2,365	1,492	1,304	Upgrade
Property, Plant & Equipment	766.11	773.64	783.47	704.22	263.61	290.16	Upgrade
Long-Term Investments	38,419	30,909	13,743	16,059	13,947	16,072	Upgrade
Other Intangible Assets	236.63	307.21	376.25	141.87	61.34	61.84	Upgrade
Total Assets	41,350	34,845	22,982	19,271	15,764	17,729	Upgrade
Accounts Payable	55.35	1,450	246.76	104.97	52.08	76.4	Upgrade
Accrued Expenses	155.77	273.4	73.96	39.99	52.77	10.18	Upgrade
Current Portion of Leases	-	-	-	8.78	2.14	6.7	Upgrade
Current Income Taxes Payable	888.8	1,123	559.61	700.03	629.43	579.08	Upgrade
Other Current Liabilities	28,882	20,815	12,086	8,985	6,200	863.97	Upgrade
Total Current Liabilities	29,982	23,662	12,966	9,839	6,936	1,583	Upgrade
Long-Term Leases	-	-	-	-	4.38	0.5	Upgrade
Long-Term Deferred Tax Liabilities	300.63	345.2	269.4	46.31	52.66	-	Upgrade
Other Long-Term Liabilities	-	-	-0	-	-	7,776	Upgrade
Total Liabilities	30,283	24,007	13,235	9,885	6,993	9,359	Upgrade
Common Stock	2,000	1,000	1,000	1,000	1,000	1,000	Upgrade
Additional Paid-In Capital	624.45	624.45	624.45	624.45	624.45	624.45	Upgrade
Retained Earnings	7,471	8,137	7,527	7,564	7,071	6,656	Upgrade
Comprehensive Income & Other	972.12	1,077	595.17	197.23	75.68	89.21	Upgrade
Shareholders' Equity	11,067	10,838	9,746	9,386	8,771	8,370	Upgrade
Total Liabilities & Equity	41,350	34,845	22,982	19,271	15,764	17,729	Upgrade
Total Debt	-	-	-	8.78	6.52	7.2	Upgrade
Net Cash (Debt)	177.02	1,191	6,208	841.87	859.67	998.55	Upgrade
Net Cash Growth	-95.96%	-80.81%	637.43%	-2.07%	-13.91%	-37.97%	Upgrade
Net Cash Per Share	0.04	0.30	1.55	0.21	0.21	0.25	Upgrade
Filing Date Shares Outstanding	4,000	4,000	4,000	4,000	4,000	4,000	Upgrade
Total Common Shares Outstanding	4,000	4,000	4,000	4,000	4,000	4,000	Upgrade
Working Capital	-28,054	-20,807	-4,887	-7,474	-5,445	-278.29	Upgrade
Book Value Per Share	2.77	2.71	2.44	2.35	2.19	2.09	Upgrade
Tangible Book Value	10,831	10,531	9,370	9,244	8,709	8,308	Upgrade
Tangible Book Value Per Share	2.71	2.63	2.34	2.31	2.18	2.08	Upgrade
Land	172.32	172.32	172.32	-	-	-	Upgrade
Buildings	513.09	499.99	499.99	263.3	200.91	200.91	Upgrade
Machinery	516.03	505.42	474.37	390.5	368.47	353.66	Upgrade
Construction In Progress	-	-	-	363.25	-	-	Upgrade

Updated Mar 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.